Omalizumab Products (Xolair, Omlyclo) coverage
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.513 alerts
Get alerted when Policy 5.01.513 changes without checking for updates manually.
Monitor payer policy activity
This policy defines medical necessity, site-of-service review, documentation, coding, and approval durations for omalizumab products (Xolair and Omlyclo) across indications including moderate-to-severe asthma, chronic idiopathic urticaria, CRSwNP, and IgE-mediated food allergy; it applies to providers submitting pharmacy or medical benefit requests to Premera Bluecross.
Updated initial authorization for all reviews from 6 months to 12 months.
Updated indication for asthma to add Exdensur (depemokimab-ulaa) to list of medications not to be used concurrently.
Updated chronic idiopathic urticaria dose limit to 600 mg every 2 weeks.
Updated asthma criteria to use maximum tolerated doses of an inhaled corticosteroid instead of maximum doses.
Updated asthma diagnostic criteria to include two or more exacerbations in previous 12 months requiring oral corticosteroids, or one or more exacerbations requiring hospitalization/ED/urgent care, or FEV1 <80% predicted, or dependence on oral corticosteroids/worsening on taper.
Policy title updated from Xolair (omalizumab) to Omalizumab Products and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.